Evolving Diagnostic Antibodies for Botulinum Neurotoxins

由肉毒杆菌产生的肉毒杆菌神经毒素BoNTs是最有效的毒素之一 人类已知的毒素。疾病控制和预防中心(CDC)已将其归类为 潜在的生物武器，A类，因为它的极端威力和杀伤力，它很容易 生产和运输，以及对受影响的人进行长期重症护理的必要性。这 该项目的重点是产生用于诊断诊断的单抗 分析方法和装置，作为了解毒素结构和功能的通用工具 两性关系。其目标是产生识别所有神经毒素亚型的单抗 血清型。将进行研究以了解抗体表位对毒素的作用 识别并利用这一知识设计单抗，从而实现更灵敏的毒素检测或 更好的治疗效果。将产生针对重链结构域的抗体作为一部分 与Project 3.1合作，目的是了解受体识别和 结合过程，并与项目3.3合作，目的是了解易位 进程。将产生针对轻链结构域的单抗，用于分析和诊断 设备。生成的样本将提供给PSWRCE合作者和其他人 在生物防御联盟工作。

The botulinum neurotoxins, BoNTs, produced by Clostridium botulinum are among the most potent toxins known to man. The Centers for Disease Control and Prevention (CDC) has classified it as a potential bio-weapon, Category A, because of its extreme potency and lethality, its ease of production and transport, and the need for prolonged intensive care among affected persons. This project focuses on generating monoclonal antibodies to be used in the development of diagnostic assays and devices and to be used as a general tool for understanding toxin structure-function relationships. The goal is to generate mAbs that recognize all neurotoxin subtypes multiple serotypes. Studies will be conducted to understand the role of antibody epitopes on toxin recognition and to use this knowledge to engineer mAbs allowing more sensitive toxin detection or greater therapeutic efficacy. Antibodies will be generated against the heavy chain domains as part of a collaboration with Project 3.1 with the aim of understanding the receptor recognition and binding process and in collaboration with Project 3.3 with the aim of understanding the translocation process. mAbs against the light chain domain will be generated for use in assays and diagnostic devices. Samples generated will be made available to PSWRCE collaborators as well as to others in the biodefense consortium.